FIXED SINGLE INJECTION DOSAGE FOR OCRELIZUMAB (2H7)

摘要

The invention relates to a use of a CD20 antagonist in the manufacture of a medicament for treatment of an autoimmune disease, wherein the medicament is for administration to a human patient in a single therapeutically effective intravenous (i.v.) infusion of said antagonist. The CD20 antagonist preferably is a CD20 antibody, and the autoimmune disease preferably is rheumatoid arthritis.